15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering NRX Pharmaceuticals Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $34.00 to $40.00, so the covering firms are broadly aligned. The average target of $37.00 sits 944% above the current $3.54. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $0.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to NRX Pharmaceuticals Inc.
As of Jul, 4 of 4 firms rate NRXP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NRXP EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 1 analysts · -84% YoY
Next period, 1 analysts expect NRX Pharmaceuticals Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus $-0.51 a year earlier. Full-year consensus is $-0.36, growing to $0.50 the year after.
REVENUE · NEXT QUARTER
$1.5M
Range $1.1M – $2.4M · 1 analysts · +540% YoY
Revenue is expected to reach $1.5M (range $1.1M – $2.4M), +539.8% year-over-year. Full-year consensus is $10.2M, rising to $165.6M next year.
Top analysts covering NRX Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NRXP.
#1
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$40.00+1028.3% to target
Overall win rate
35%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$34.00+859.1% to target
Overall win rate
22%
+ Follow
#3
EW
Edward Woo
Ascendiant
Buy
$48.00+1254.0% to target
Coverage
—
+ Follow
NRXP stock forecast FAQ
What is NRXP's average 12-month price target?+
The 2 analysts with a live target average $37.00 for NRX Pharmaceuticals Inc over the next 12 months, ranging from a $40.00 high to a $34.00 low.
Is NRXP stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NRXP?+
The Street-high target is $40.00 (HC Wainwright & Co.), and the Street-low is $34.00 (D. Boral Capital). The average of all 2 active targets is $37.00.
How many Wall Street analysts cover NRXP?+
4 analysts have an active rating on NRX Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NRXP?+
Among analysts who currently cover NRXP, Patrick R. Trucchio of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #203). Their current call is Buy with a $40.00 target.
What is NRX Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 1 analysts. Full-year EPS is projected at $-0.36, rising to $0.50 the following year.
How much revenue is NRX Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $1.5M (range $1.1M – $2.4M). Full-year revenue is projected at $10.2M, growing to $165.6M next year.
Have analysts been upgrading or downgrading NRXP lately?+
As of Jul, 4 of 4 firms rate NRXP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NRXP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
